WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
LOS ANGELES, April 20, 2017 -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO) concerning possible violations of federal securities laws between November 14, 2013 and April 10, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 13, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, during the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that the Company, through its former Chief Executive Officer (“CEO”) Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
